Globenewswire·2026-03-12 12:30Core Insights - Celularity Inc. has announced a strategic commercialization partnership with NEXGEL, Inc. to leverage regulatory clarity around placental-derived biomaterials and enhance sales and market share, with the transaction expected to close by April 15, 2026 [1][4] Company Overview - Celularity Inc. focuses on regenerative and cellular medicine, developing therapies from postpartum placenta to target aging and age-related diseases [3] Partnership Details - The partnership allows Celularity to concentrate on contract manufacturing, where it has a proven track record in cost-efficient biomaterial production at a pharmaceutical-grade level [2] - NEXGEL is identified as an ideal partner due to its disciplined approach and ability to drive market growth across various industry verticals [2] Product and Manufacturing - Celularity will exclusively manufacture licensed products at its FDA-compliant facility in Florham Park, New Jersey, supporting scalable production for both commercial products and next-generation therapies [7] - The partnership includes established commercial products like Biovance and potential market disruptors from pipeline programs such as SPARK, FUSE, and ORCHID [7]